Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
| ▸ | NT5E | P21589 | 6/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14767406 | 0.95 | PRKCG (0.68) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL13814597 | 0.95 | NR1H4 (0.67) | PRKCGTRPV1NR1H4 | |
| SCHEMBL12557901 | 0.93 | TRPV1 (0.65) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL12557856 | 0.93 | RORC (0.65) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL12557832 | 0.93 | TRPV1 (0.68) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL12557862 | 0.92 | TRPV1 (0.62) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL13811950 | 0.92 | TRPV1 (0.64) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL12557849 | 0.92 | PRKCG (0.67) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL12557879 | 0.92 | TRPV1 (0.64) | PRKCGTRPV1PRKCDNT5ECETP | |
| SCHEMBL12557834 | 0.91 | TRPV1 (0.69) | PRKCGTRPV1PRKCDNT5ECETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090149429-A1 | ANTIVIRAL COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149429-A1 | ANTIVIRAL COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | PRKCG 3008/4885TRPV1 372/4885PRKCD 3851/4885 |
| US-20090149429-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, MAVS, EIF2AK2 | PRKCG 3317/4885TRPV1 3298/4885PRKCD 4069/4885 |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | PRKCG 3008/4885TRPV1 372/4885PRKCD 3851/4885 |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | PRKCG 3008/4885TRPV1 372/4885PRKCD 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.